GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All conditions

GLP-1 Therapy for Fatty Liver (NAFLD/MASLD) in India

Last reviewed 12 May 2026 · Indian guideline context

The short answer

GLP-1 therapy (semaglutide, tirzepatide) shows strong evidence for reducing liver fat, improving liver enzymes, and resolving steatohepatitis (MASH) in trials. In India, GLP-1 is prescribed for NAFLD/MASLD under the obesity or T2D indication — BMI ≥27.5 (or ≥25 with comorbidities) is typical eligibility. Direct DCGI approval for MASH/NAFLD indication is not yet in place. Take the 5-min eligibility check.

See if you’re a candidate

The 5-minute Indian-guideline eligibility check factors in your Fatty Liver (NAFLD/MASLD) status.

Take the free assessment →

Fatty Liver (NAFLD/MASLD) in India — the context

India has one of the highest NAFLD prevalences globally — estimated 32% of adults in urban India (rising sharply with diabetes and obesity prevalence). The Indian phenotype shows aggressive progression: NAFLD → NASH/MASH → fibrosis → cirrhosis can occur in 15-25% of NAFLD patients over 10-15 years, often at lower BMI than Western patients. INASL (Indian National Association for Study of Liver) 2024 guidelines emphasize early intervention with weight loss + metabolic optimization, with GLP-1 increasingly cited as a useful tool in obesity-comorbid NAFLD.

How GLP-1 helps — mechanism + evidence

GLP-1 receptor agonists improve liver fat content (often 30-50% reduction at 6-12 months in trials), reduce serum ALT and AST, and have shown histological improvement in NASH/MASH. The mechanism is largely indirect — weight loss + insulin sensitivity improvement → reduced hepatic fat synthesis + improved liver metabolic profile. Tirzepatide MRI-PDFF substudies (from the SURPASS-3 imaging substudy and SURMOUNT-1 secondary outcomes) showed strong liver-fat reduction. The ESSENCE Phase 3 trial (semaglutide 2.4 mg weekly for MASH, published NEJM 2025) achieved 62.9% NASH resolution at week 72 vs 34.3% placebo, plus fibrosis reduction in 36.8% vs 22.4% — the strongest dedicated MASH evidence for any GLP-1 to date.

Key trials

  • ESSENCE Phase 3 (semaglutide MASH, NEJM 2025): Semaglutide 2.4 mg weekly achieved NASH resolution without worsening of fibrosis in 62.9% of patients vs 34.3% placebo at 72 weeks. Fibrosis reduction (without worsening of steatohepatitis) in 36.8% vs 22.4%. Combined endpoint in 32.7% vs 16.1%.
  • Newsome et al. Phase 2 (NEJM 2021): Semaglutide 0.4 mg subcutaneous daily achieved NASH resolution in 59% of patients vs 17% placebo at 72 weeks; fibrosis not worsened. This Phase 2 trial established the molecule's MASH activity and motivated the Phase 3 ESSENCE programme.
  • SURPASS-3 MRI substudy (tirzepatide): Tirzepatide reduced liver fat content (measured by MRI-PDFF) by 30-50% in T2D patients with NAFLD; ALT and AST improved consistently. Dedicated MASH outcome trials with tirzepatide (SYNERGY-NASH and successors) are ongoing.
  • STEP and SURMOUNT (subgroup analyses): Weight loss in obese patients with NAFLD subgroups consistently improved liver enzymes and imaging markers of hepatic steatosis.

Eligibility — who fits?

In India, GLP-1 for NAFLD/MASLD is currently prescribed under the obesity indication (BMI ≥27.5 or ≥25 with comorbidities) or the T2D indication (when both conditions co-exist). Direct NAFLD/MASH indication is not yet DCGI-approved. The 5-min GLP-1 Check assessment factors in BMI, waist circumference, HbA1c, LFT results, and family history to map your fit.

Indian-context considerations

  • •NAFLD is often silent — many Indians discover it on an incidental ultrasound or LFT during routine checkup; once diagnosed, early intervention matters
  • •Concurrent metabolic syndrome (T2D, hypertension, dyslipidaemia) is the norm in Indian NAFLD — GLP-1 addresses multiple drivers simultaneously
  • •Alcohol intake must be honestly disclosed — even moderate alcohol substantially worsens NAFLD; some patients may have mixed-aetiology liver disease
  • •Indian vegetarian diets that are heavy in refined carbohydrates, ghee, and fried foods can drive NAFLD; pair GLP-1 with dietary review
  • •Advanced fibrosis (F3-F4) requires hepatologist co-management; GLP-1 is an adjunct, not a substitute for specialist liver care

Brand options for Fatty Liver (NAFLD/MASLD)

Wegovy

Strongest dedicated MASH evidence (ESSENCE Phase 3, NEJM 2025: 62.9% resolution at 2.4 mg weekly). On-label for obesity (the umbrella indication for NAFLD prescribing in India until a direct MASH label is approved).

Mounjaro

Strong liver-fat reduction in substudies; aggressive weight loss; on-label for both T2D and obesity — useful in NAFLD + comorbidity.

Ozempic

When NAFLD + T2D coexist, Ozempic's T2D indication aligns; weight + liver outcomes are good but smaller than Wegovy/Mounjaro doses.

Full brand catalog: Semaglutide brands in India → · India pricing →

Patient pathway

Typical NAFLD pathway: (1) take the 5-min GLP-1 Check assessment; (2) hepatologist + endocrinologist consult — assess severity (FibroScan or transient elastography, MRI-PDFF if available); (3) baseline labs (LFT, HbA1c, lipid profile, fasting insulin); (4) discuss therapy options under the obesity or T2D indication; (5) titrate GLP-1 over 12-16 weeks; (6) follow-up at 6 months with repeat LFT, weight, and imaging (FibroScan or USG) to assess response.

Frequently asked questions

Will GLP-1 reverse my fatty liver?+
In many cases, yes — particularly for simple NAFLD without advanced fibrosis. Trials consistently show 30-50% reduction in liver fat content over 6-12 months with semaglutide or tirzepatide at standard doses. NASH/MASH resolution (the inflammatory stage) was achieved in 62.9% of patients on semaglutide 2.4 mg weekly vs 34.3% placebo in the ESSENCE Phase 3 trial at 72 weeks (NEJM 2025). The earlier Newsome Phase 2 trial (NEJM 2021) at semaglutide 0.4 mg daily showed 59% resolution vs 17% placebo. Advanced fibrosis (F3-F4) responds more slowly.
Is semaglutide approved for MASH/NAFLD in India?+
Not directly. Current DCGI approvals are for T2D (Ozempic) and obesity (Wegovy, Mounjaro). MASH/NAFLD prescribing happens under these umbrella indications when BMI/T2D criteria are met. The ESSENCE Phase 3 trial of semaglutide 2.4 mg weekly for MASH was published in NEJM 2025 with strong efficacy (62.9% NASH resolution); a direct MASH indication is expected to follow FDA/DCGI label review.
Do I need a hepatologist or endocrinologist for fatty liver?+
Both, ideally. Endocrinologist manages the metabolic side (BMI, T2D, GLP-1 prescribing) and hepatologist manages liver-specific evaluation (FibroScan, biopsy if needed, monitoring fibrosis progression). In Indian metros (Delhi NCR, Mumbai, Pune, Chennai, Bangalore), many hospitals have integrated metabolic + liver clinics that handle both.
Can lean Indians have NAFLD and still benefit from GLP-1?+
Lean NAFLD is increasingly recognized in Indian patients. GLP-1 use in lean NAFLD is more nuanced — typically not first-line, but may be considered if insulin resistance is documented, family history is strong, and standard interventions have failed. Direct prescribing requires specialist judgment.
How long until my LFT (ALT/AST) values improve on GLP-1?+
Typically within 3-6 months. ALT often drops faster than AST. Many patients see normalization (<40 U/L) by 6-12 months on therapy, particularly when paired with sustained dietary change. Persistent elevation despite GLP-1 therapy + weight loss warrants further liver workup.
Will I need a liver biopsy?+
In India, FibroScan (transient elastography) and MRI-PDFF are increasingly replacing liver biopsy for staging NAFLD/MASH. Biopsy is reserved for unclear diagnoses, suspected co-existing liver disease, or clinical trial enrollment. Most Indian metros have hospitals offering FibroScan as a routine outpatient test.
Are Indian generic semaglutides effective for fatty liver?+
Same molecule, same biological effect. Indian generic semaglutides (Sundae, Noveltreat, Obeda, etc.) deliver the same active drug as Ozempic and Wegovy — the cost difference is in brand, manufacturer, and pen design, not the molecule itself. For NAFLD where long-term therapy is often needed, generics offer substantial cost savings (₹1,290–3,500 vs ₹5,660+/month).

Related conditions

Type 2 Diabetes

GLP-1 for Type 2 Diabetes — Indian context

Prediabetes

GLP-1 for Prediabetes — Indian context

PCOS

GLP-1 for PCOS — Indian context

Hypertension

GLP-1 for Hypertension — Indian context

See if GLP-1 fits your Fatty Liver (NAFLD/MASLD) profile

5 minutes. Uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Take the free assessment →

Educational content based on DCGI-approved labelling, peer-reviewed trials, RSSDI/ESI/INASL Indian clinical guidelines, and published literature. Not a substitute for a doctor’s clinical judgment. GLP-1 therapies are Schedule H drugs in India and require a doctor’s prescription. Always consult a qualified medical practitioner before starting any therapy.